Aaron Robinson, PhD
About Aaron Robinson, PhD
Aaron Robinson, PhD, is a Mass Spectrometry Scientist III at Amunix Pharmaceuticals, specializing in quantitative mass spectrometry-based discovery proteomics. He focuses on experimental design and data analysis to enhance understanding of protease environments in tumors and inflammation.
Work at Amunix Pharmaceuticals
Aaron Robinson serves as a Mass Spectrometry Scientist III at Amunix Pharmaceuticals, a position he has held since 2020. In this role, he focuses on quantitative mass spectrometry-based discovery proteomics screens, utilizing advanced methodologies and instrumentation. His work contributes to the understanding of protease environments and substrate specificity in tumors and inflammation, aligning with the company's goals in biopharma research.
Education and Expertise
Aaron Robinson earned his Doctor of Philosophy (Ph.D.) in Biomedical Science and Translational Medicine from Cedars-Sinai, where he studied from 2014 to 2019. He also holds a Bachelor of Science degree in Animal Biotechnology with a minor in Technology Management from the University of California, Davis, completed in 2009. His expertise includes quantitative mass spectrometry techniques such as DIA-MS, MRM-HR, and DDA-MS, particularly on Orbitrap and TOF instruments.
Background in Research
Aaron Robinson has a diverse research background, having worked at several prestigious institutions. He was a Postdoctoral Researcher at Cedars-Sinai in the Van Eyk Lab from 2014 to 2020 and at Stanford University School of Medicine in the Snyder Lab for one year. Prior to that, he served as a Research Specialist/Laboratory Manager in the Phillips Lab at the University of California, San Francisco, and as a Research Assistant in the Powell Lab at UC Davis.
Professional Experience
Throughout his career, Aaron Robinson has held various research positions that have enhanced his skills in mass spectrometry and data analysis. He worked as a Research Scientist at Tricida, Inc. for five months in 2014. His responsibilities have included experimental design, mass spectrometry operations, and the analysis of complex datasets, which are crucial for advancing understanding in proteomics.
Research Interests
Aaron Robinson is interested in applying mass spectrometry-based proteomics analyses to better understand and subtype complex diseases. His aim is to contribute to personalized medicine by leveraging mass spectrometry to improve patient outcomes through targeted drug treatments. This focus aligns with current trends in biopharma research and the need for precision in therapeutic approaches.